CN106008477A - 3-(2-芳基-1h-吲哚-3-基)-4-羟基呋喃-2(5h)-酮及其合成方法 - Google Patents
3-(2-芳基-1h-吲哚-3-基)-4-羟基呋喃-2(5h)-酮及其合成方法 Download PDFInfo
- Publication number
- CN106008477A CN106008477A CN201610389382.0A CN201610389382A CN106008477A CN 106008477 A CN106008477 A CN 106008477A CN 201610389382 A CN201610389382 A CN 201610389382A CN 106008477 A CN106008477 A CN 106008477A
- Authority
- CN
- China
- Prior art keywords
- acid
- aryl
- indol
- furan
- synthetic method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000010189 synthetic method Methods 0.000 title claims description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 30
- 150000001875 compounds Chemical class 0.000 claims abstract description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 22
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000003054 catalyst Substances 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims abstract description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Chemical class CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 claims abstract description 11
- PEQJBOMPGWYIRO-UHFFFAOYSA-N n-ethyl-3,4-dimethoxyaniline Chemical class CCNC1=CC=C(OC)C(OC)=C1 PEQJBOMPGWYIRO-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000002904 solvent Substances 0.000 claims abstract description 9
- 150000001448 anilines Chemical class 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 7
- 230000005855 radiation Effects 0.000 claims abstract description 5
- 150000007529 inorganic bases Chemical class 0.000 claims abstract description 4
- 150000002825 nitriles Chemical class 0.000 claims abstract description 4
- 150000007524 organic acids Chemical class 0.000 claims abstract description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 32
- VIHAEDVKXSOUAT-UHFFFAOYSA-N but-2-en-4-olide Chemical compound O=C1OCC=C1 VIHAEDVKXSOUAT-UHFFFAOYSA-N 0.000 claims description 27
- 238000006243 chemical reaction Methods 0.000 claims description 24
- 230000004044 response Effects 0.000 claims description 12
- 230000015572 biosynthetic process Effects 0.000 claims description 11
- 238000003786 synthesis reaction Methods 0.000 claims description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- -1 arene compound Chemical class 0.000 claims description 9
- ZXPNUUFATNGXAW-UHFFFAOYSA-N benzene;oxaldehyde Chemical class O=CC=O.C1=CC=CC=C1 ZXPNUUFATNGXAW-UHFFFAOYSA-N 0.000 claims description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical group [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- 241001597008 Nomeidae Species 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 239000001117 sulphuric acid Substances 0.000 claims description 3
- 235000011149 sulphuric acid Nutrition 0.000 claims description 3
- 238000010490 three component reaction Methods 0.000 claims description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 2
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 150000001299 aldehydes Chemical class 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 abstract description 5
- 238000006452 multicomponent reaction Methods 0.000 abstract description 5
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract description 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract description 3
- 238000001308 synthesis method Methods 0.000 abstract 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 abstract 1
- 235000019606 astringent taste Nutrition 0.000 abstract 1
- 150000003935 benzaldehydes Chemical class 0.000 abstract 1
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzenecarboxaldehyde Natural products O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 abstract 1
- 238000009835 boiling Methods 0.000 abstract 1
- 150000007522 mineralic acids Chemical class 0.000 abstract 1
- 238000005580 one pot reaction Methods 0.000 abstract 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 abstract 1
- 230000035484 reaction time Effects 0.000 abstract 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 18
- 239000003814 drug Substances 0.000 description 11
- 238000005160 1H NMR spectroscopy Methods 0.000 description 9
- 238000004440 column chromatography Methods 0.000 description 9
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 9
- OJUGVDODNPJEEC-UHFFFAOYSA-N phenylglyoxal Chemical compound O=CC(=O)C1=CC=CC=C1 OJUGVDODNPJEEC-UHFFFAOYSA-N 0.000 description 7
- 0 *=C1O[C@@](C(CO)O)C(O)=C1O Chemical compound *=C1O[C@@](C(CO)O)C(O)=C1O 0.000 description 5
- WDFQBORIUYODSI-UHFFFAOYSA-N 4-bromoaniline Chemical compound NC1=CC=C(Br)C=C1 WDFQBORIUYODSI-UHFFFAOYSA-N 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 150000002475 indoles Chemical class 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 125000006237 oxymethylenoxy group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- WRDWWAVNELMWAM-UHFFFAOYSA-N 4-tert-butylaniline Chemical compound CC(C)(C)C1=CC=C(N)C=C1 WRDWWAVNELMWAM-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 235000002566 Capsicum Nutrition 0.000 description 2
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 2
- 240000008384 Capsicum annuum var. annuum Species 0.000 description 2
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 2
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 2
- JCGNDDUYTRNOFT-UHFFFAOYSA-N O=C(C1)COC1=O Chemical compound O=C(C1)COC1=O JCGNDDUYTRNOFT-UHFFFAOYSA-N 0.000 description 2
- 239000006002 Pepper Substances 0.000 description 2
- 241000722363 Piper Species 0.000 description 2
- 235000016761 Piper aduncum Nutrition 0.000 description 2
- 235000017804 Piper guineense Nutrition 0.000 description 2
- 235000008184 Piper nigrum Nutrition 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000002391 heterocyclic compounds Chemical class 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 229960005127 montelukast Drugs 0.000 description 2
- 239000000575 pesticide Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- JLUQTCXCAFSSLD-NXEZZACHSA-N Anemonin Chemical compound C1=CC(=O)O[C@]11[C@@]2(C=CC(=O)O2)CC1 JLUQTCXCAFSSLD-NXEZZACHSA-N 0.000 description 1
- JLUQTCXCAFSSLD-UHFFFAOYSA-N Anemonin Natural products C1=CC(=O)OC11C2(C=CC(=O)O2)CC1 JLUQTCXCAFSSLD-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- JBNBNDGMKZGCHD-UHFFFAOYSA-N C1=CC=C(C=C1)C(=O)CC(=O)Br Chemical compound C1=CC=C(C=C1)C(=O)CC(=O)Br JBNBNDGMKZGCHD-UHFFFAOYSA-N 0.000 description 1
- XGLJSTBIMWPDQW-UHFFFAOYSA-N CC(C(C=N)=C1O)OC1=O Chemical compound CC(C(C=N)=C1O)OC1=O XGLJSTBIMWPDQW-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000903946 Clematidis Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000030595 Glucokinase Human genes 0.000 description 1
- 108010021582 Glucokinase Proteins 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000000895 acaricidal effect Effects 0.000 description 1
- 239000000642 acaricide Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000003555 analeptic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- HWNMGFXHZYIMRO-UHFFFAOYSA-N benzene-1,4-diol;1h-indole Chemical compound OC1=CC=C(O)C=C1.C1=CC=C2NC=CC2=C1 HWNMGFXHZYIMRO-UHFFFAOYSA-N 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940103177 maxalt Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 108091008765 peroxisome proliferator-activated receptors β/δ Proteins 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- UOWVMDUEMSNCAV-WYENRQIDSA-N rachelmycin Chemical compound C1([C@]23C[C@@H]2CN1C(=O)C=1NC=2C(OC)=C(O)C4=C(C=2C=1)CCN4C(=O)C1=CC=2C=4CCN(C=4C(O)=C(C=2N1)OC)C(N)=O)=CC(=O)C1=C3C(C)=CN1 UOWVMDUEMSNCAV-WYENRQIDSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- ULFRLSNUDGIQQP-UHFFFAOYSA-N rizatriptan Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1CN1C=NC=N1 ULFRLSNUDGIQQP-UHFFFAOYSA-N 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- DTDSAWVUFPGDMX-UHFFFAOYSA-N spirodiclofen Chemical compound CCC(C)(C)C(=O)OC1=C(C=2C(=CC(Cl)=CC=2)Cl)C(=O)OC11CCCCC1 DTDSAWVUFPGDMX-UHFFFAOYSA-N 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种3‑(2‑芳基‑1H‑吲哚‑3‑基)‑4‑羟基呋喃‑2(5H)‑酮的合成方法,该合成方法是以取代苯甲酰甲醛、取代苯胺和季酮酸为原料,以醇、醚、腈、水、二甲亚砜、N,N‑二甲基甲酰胺、醋酸或芳香烃化合物为溶剂,在不使用催化剂,或以无机碱、无机酸、有机酸或有机小分子化合物为催化剂的情况下,在微波辐射下利用多组分反应,将这三种原料通过“一锅煮”的方法合成了一种同时具有呋喃‑2(5H)‑酮和吲哚两种骨架的新型化合物。本发明的合成方法具有反应时间较短,条件较为简单,高产率,高原子经济性,收敛性以及易操作等优点。
Description
技术领域
本发明属于有机化合成领域,具体而言,涉及一种3-(2-芳基-1H-吲哚-3-基)-4-羟基呋喃-2(5H)-酮及其合成方法。
背景技术
呋喃-2(5H)-酮是一种重要的呋喃类杂环化合物,它广泛存在自然界中,维生素C(结构式1)和青霉酸(结构式2)是人们最为熟悉的呋喃-2(5H)-酮衍生物。4,5-二甲基-3-羟基呋喃-2(5H)-酮(结构式3)是一种具有香味的物质(R.Kazlauskas,P.T.Murphy,R.J.Quinn,R.J.Wells,Tetrahedron Lett.,1977,18,37)。某些重要中药的有效成分,也含有呋喃-2(5H)-酮结构的化合物,例如:威灵仙中的白头翁素(结构式4)等(吕丹,海峡药学,1999,11,7)。
呋喃-2(5H)-酮结构的化合物具有广泛的生物和药理学活性,例如:抗真菌、抗炎、抗病毒、抗癌等等((a)G.Grossmann,M.Poncioni,M.Bornand,B.Jolivet,M.Neuburger,U.Sequin,Tetrahedron,2003,59,3237.)。近几年又发现该类骨架的化合物具有抑制细菌群体效应的活性((a)M.Hentzer,K.Riedel,T.B.Rasmussen,A.Heydorn,J.B.Andersen,M.R.Parsen,S.A.Rice,L.Eberl,S.Molin,N.Hoiby,S.Kjelleberg,M.Givskov,Microbiology,2002,148,87;(b)D.Ren,R.Zuo,T.K.Wood,Applied Microbiology and Biotechnology,2005,66,689.)。一些具有呋喃-2(5H)-酮结构的化合物研究应用于药物和农药中,例如:新型非甾体抗炎药物罗昔布(rofecoxib,MK 966)(结构式5)(嵇汝运,国外医药合成药,生化药,制剂分册,1999,20,258.)和农药杀螨剂螺螨酯(结构式6)(R.Fischer,T.Bretschneider,B.W.Krueger,DE,4216814,1993.01.21.)及螺虫酯(结构式7)(U.Wachendorff-Neumann,WO,20000042850,2000.07.27.)都具有呋喃-2(5H)-酮骨架。
吲哚类化合物是自然界中分布最广的杂环化合物,作为医药、农药、染料和其它精细化工产品的中间体,其应用越来越广。首先,吲哚环在许多药物中是一个重要的骨架,比如治疗成年人和儿童哮喘的新药顺尔宁(Singulair),以及治疗偏头痛药物(Maxalt);同样,针对结肠、乳腺癌细胞具有高选择性的抗肿瘤活性的吲哚-醌醇化合物,其结构式为(A.J.McCarroll,T.D.Bradshaw,A.D.Westwell,C.S.Matthews,M.F.G.Stevens.J.Med.Chem.,2007,50,1707);吲哚衍生物可作为神经保护药物,高效阿片受体兴奋剂,治疗骨质疏松症药物PPAR-c,治疗周围神经病变以及神经退化疾病的药物,葡萄糖激酶活化剂,细胞毒性抗生素CC-1065和它的前体药物,以及治疗心血管疾病催化剂PPAR-delta(G.Bratulescu,Tetrahedron Lett.,2008,49,984)。
多组分反应就是一种符合环境友好型的合成方法学,多组分反应是将三个或者三个以上的原料通过“一锅煮”的方法合成包含所有组分主要结构片段的新化合物的过程。多组分具有高产率、高原子经济性、收敛性以及易操作等优点。通过多组分反应可以利用一些简单易得的原料,方便、高效地构建具有结构多样性和复杂性的化合物,该方法已经广泛应用于各种杂环化合物的合成。
发明内容
基于呋喃-2(5H)-酮骨架和吲哚骨架所具有的重要的生物和药理学活性,本发明的目的是利用多组分反应的合成方法,一步合成一种同时具有呋喃-2(5H)-酮和吲哚两种骨架的新型化合物,该种新型化合物具有潜在应用价值。
为实现上述技术目的,达到上述技术效果,本发明通过以下技术方案实现:
一种3-(2-芳基-1H-吲哚-3-基)-4-羟基呋喃-2(5H)-酮,其结构如下所示:
其中,R1为H、4-CH3或4-Br中的任意一种;R2为5-Br、5-CH3、5-(CH3)3C、5,6-OCH2O或4-Cl中的任意一种。
一种3-(2-芳基-1H-吲哚-3-基)-4-羟基呋喃-2(5H)-酮的合成方法,是以取代苯甲酰甲醛(式I)、取代苯胺(式II)和季酮酸(式III)为原料,以醇、醚、腈、水、二甲亚砜、N,N-二甲基甲酰胺、醋酸或芳香烃化合物为溶剂,在不使用催化剂,或以无机碱、无机酸、有机酸或有机小分子化合物为催化剂的情况下,在微波辐射下经过三组分反应,一步合成得到目标化合物,一步合成得到目标化合物,即3-(2-芳基-1H-吲哚-3-基)-4-羟基呋喃-2(5H)-酮衍生物(式IV):
其反应式如下:
进一步的,所述溶剂为甲醇、乙醇、1,4-二氧六环、四氢呋喃、乙腈、N,N-二甲基甲酰胺、二甲亚砜、醋酸、甲苯、水或水与乙醇的混合溶剂中的任意一种。
进一步的,所述催化剂为碳酸钠、碳酸钾、盐酸、硫酸、醋酸、三氟乙酸、对甲苯磺酸或L-脯氨酸中的任意一种。
进一步的,所述取代苯甲酰甲醛、所述取代苯胺、所述季酮酸和所述催化剂的摩尔比为1:1:1:0.1~1:1:1:0.3。
进一步的,该反应的反应时间为20~50分钟。
进一步的,该反应的反应温度为60~100℃。
经过多次反应条件的筛选,并考虑到反应的效果和绿色化学的原则,作为优选,确定以水和乙醇组成(体积比为1:1)的混合溶剂作为溶剂,以三氟乙酸作为催化剂,将取代苯甲酰甲醛、取代苯胺、季酮酸和三氟乙酸按照1:1:1:0.2的摩尔比,在反应温度为90℃的条件下反应40分钟,得到的目标产物的收率最高。
本发明的有益效果是:
本发明的合成方法利用多组分反应,将三种原料通过“一锅煮”的方法合成了一种同时具有呋喃-2(5H)-酮和吲哚两种骨架的新型化合物,该种新型化合物具有的重要的生物和药理学活性,以及具有潜在应用价值。与现有技术相比,本发明的合成方法具有反应时间较短,条件较为简单,高产率,高原子经济性,收敛性以及易操作等优点。
上述说明仅是本发明技术方案的概述,为了能够更清楚了解本发明的技术手段,并可依照说明书的内容予以实施,以下以本发明的较佳实施例详细说明。本发明的具体实施方式由以下实施例详细给出。
具体实施方式
下面将结合实施例,来详细说明本发明。
一种3-(2-芳基-1H-吲哚-3-基)-4-羟基呋喃-2(5H)-酮,其结构如下所示:
其中,R1为H、4-CH3或4-Br中的任意一种;R2为5-Br、5-CH3、5-(CH3)3C、5,6-OCH2O或4-Cl中的任意一种。
一种3-(2-芳基-1H-吲哚-3-基)-4-羟基呋喃-2(5H)-酮的合成方法,是以取代苯甲酰甲醛(式I)、取代苯胺(式II)和季酮酸(式III)为原料,以醇、醚、腈、水、二甲亚砜、N,N-二甲基甲酰胺、醋酸或芳香烃化合物为溶剂,在不使用催化剂,或以无机碱、无机酸、有机酸或有机小分子化合物为催化剂的情况下,在微波辐射下经过三组分反应,一步合成得到目标化合物,一步合成得到目标化合物,即3-(2-芳基-1H-吲哚-3-基)-4-羟基呋喃-2(5H)-酮衍生物(式IV):
其反应式如下:
本发明的合成方法,是由取代苯甲酰甲醛、取代苯胺、季酮酸、催化剂和适当溶剂所组成的反应体系在微波辐射下进行的。其中,所述取代苯甲酰甲醛、所述取代苯胺、所述季酮酸和所述催化剂的摩尔比为1:1:1:0.1~1:1:1:0.3。
本发明的合成方法中所使用的溶剂为甲醇、乙醇、1,4-二氧六环、四氢呋喃、乙腈、N,N-二甲基甲酰胺、二甲亚砜、醋酸、甲苯、水或水与乙醇的混合溶剂中的任意一种。
本发明的合成方法中所使用的催化剂为碳酸钠、碳酸钾、盐酸、硫酸、醋酸、三氟乙酸、对甲苯磺酸或L-脯氨酸中的任意一种。
本发明的合成方法的反应时间为20~50分钟。
本发明的合成方法的反应温度为60~100℃。
经过多次反应条件的筛选,并考虑到反应的效果和绿色化学的原则,作为优选,确定以水和乙醇组成(体积比为1:1)的混合溶剂作为溶剂,以三氟乙酸作为催化剂,将取代苯甲酰甲醛、取代苯胺、季酮酸和三氟乙酸按照1:1:1:0.2的摩尔比,在反应温度为90℃的条件下反应40分钟,得到的目标产物的收率最高。
下面由以下实施例对该种3-(2-芳基-1H-吲哚-3-基)-4-羟基呋喃-2(5H)-酮的合成方法进行详细举例和说明:
实施例1
将苯甲酰甲醛(1mmol)、对溴苯胺(1mmol)、季酮酸(1mmol)加入微波反应管,加入4mL EtOH/H2O(体积比为1:1),稍加震荡使底物混合均匀,滴加(0.2mmol)三氟乙酸,微波反应器于90℃反应40min,用TLC监测反应进程,待反应结束后通过柱层析得到产物,为3-(5-溴-2-苯基-1H-吲哚-3-基)-4-羟基呋喃-2(5H)-酮(化合物IVa),收率为65%。化合物的结构通过核磁共振谱确定。熔点为280~282℃。1H NMR(400MHz,DMSO-d6)δ(ppm):12.19(s,1H,OH),11.76(s,1H,NH),7.67(d,J=7.6Hz,2H,ArH),7.45(s,1H,ArH),7.44(t,J=7.6Hz,2H,ArH),7.40-7.32(m,2H,ArH),7.25(d,J=8.4Hz,1H,ArH),4.87(s,2H,CH2)。
实施例2
按照实施例1的方法,将对溴苯胺换成对甲苯胺,加入(0.2mmol)三氟乙酸,微波反应器于90℃反应40min,用TLC监测反应进程,待反应结束后通过柱层析得到产物,为3-(5-甲基-2-苯基-1H-吲哚-3-基)-4-羟基呋喃-2(5H)-酮(化合物IVb),收率为57%,熔点为276~277℃。1H NMR(400MHz,DMSO-d6)δ(ppm):11.95(s,1H,OH),11.39(s,1H,NH),7.65(d,J=7.6Hz,2H,ArH),7.42(t,J=7.6Hz,2H,ArH),7.30(t,J=8.4Hz,2H,ArH),7.09(s,1H,ArH),6.96(d,J=8.4Hz,1H,ArH),4.85(s,2H,CH2),2.37(s,3H,CH3)。
实施例3
按照实施例1的方法,将对溴苯胺换成对叔丁基苯胺,加入(0.2mmol)三氟乙酸,微波反应器于90℃反应40min,用TLC监测反应进程,待反应结束后通过柱层析得到产物,为3-(5-叔丁基-2-苯基-1H-吲哚-3-基)-4-羟基呋喃-2(5H)-酮(化合物IVc),收率为71%,熔点为250~251℃。1H NMR(400MHz,DMSO-d6)δ(ppm):11.53(s,1H,OH),11.38(s,1H,NH),7.65(d,J=7.2Hz,2H,ArH),7.42(t,J=7.6Hz,2H,ArH),7.35(d,J=8.4Hz,1H,ArH),7.30(t,J=7.2Hz,2H,ArH),7.24(d,J=8.8Hz,1H,ArH),4.88(s,2H,CH2),1.33(s,9H,(CH3)3C)。
实施例4
按照实施例1的方法,将对溴苯胺换成3,4-亚甲二氧基苯胺(胡椒胺),加入(0.2mmol)三氟乙酸,微波反应器于90℃反应40min,用TLC监测反应进程,待反应结束后通过柱层析得到产物,为3-(5,6-亚甲二氧基-2-苯基-1H-吲哚-3-基)-4-羟基呋喃-2(5H)-酮(化合物IVd),收率为72%,熔点为244~246℃。1H NMR(400MHz,DMSO-d6)δ(ppm):12.09(s,1H,OH),11.38(s,1H,NH),7.62(d,J=7.6Hz,2H,ArH),7.40(t,J=7.6Hz,2H,ArH),7.26(t,J=7.2Hz,1H,ArH),6.94(s,1H,ArH),6.77(s,1H,ArH),5.96(s,2H,OCH2O),4.86(s,2H,CH2)。
实施例5
按照实施例1的方法,将苯甲酰甲醛换成对甲基苯甲酰甲醛,加入(0.2mmol)三氟乙酸,微波反应器于90℃反应40min,用TLC监测反应进程,待反应结束后通过柱层析得到产物,为3-(5-溴-2-对甲苯基-1H-吲哚-3-基)-4-羟基呋喃-2(5H)-酮(化合物IVe),收率为64%,熔点为266~267℃。1H NMR(400MHz,DMSO-d6)δ(ppm):12.17(s,1H,OH),11.70(s,1H,NH),7.56(d,J=8.0Hz,2H,ArH),7.47(s,1H,ArH),7.37(d,J=8.4Hz,1H,ArH),7.26-7.22(m,3H,ArH),4.86(s,2H,CH2),2.34(s,3H,CH3)。
实施例6
按照实施例4的方法,将对溴苯胺换成3,4-亚甲二氧基苯胺(胡椒胺),加入(0.2mmol)三氟乙酸,微波反应器于90℃反应40min,用TLC监测反应进程,待反应结束后通过柱层析得到产物,为3-(5,6-亚甲二氧基-2-对甲苯基-1H-吲哚-3-基)-4-羟基呋喃-2(5H)-酮(化合物IVf),收率为78%,熔点为280~281℃。1H NMR(400MHz,DMSO-d6)δ(ppm):12.05(s,1H,OH),11.30(s,1H,NH),7.49(d,J=7.6Hz,2H,ArH),7.20(d,J=8.0Hz,2H,ArH),6.92(s,1H,ArH),6.74(s,1H,ArH),5.95(s,2H,OCH2O),4.84(s,2H,CH2),2.32(s,3H,CH3)。
实施例7
按照实施例4的方法,将3,4-亚甲二氧基苯胺(胡椒胺)换成对叔丁基苯胺,加入(0.2mmol)三氟乙酸,微波反应器于90℃反应40min,用TLC监测反应进程,待反应结束后通过柱层析得到产物,为3-(5-叔丁基-2-对甲苯基-1H-吲哚-3-基)-4-羟基呋喃-2(5H)-酮(化合物IVg),收率为69%,熔点为268~270℃。1H NMR(400MHz,DMSO-d6)δ(ppm):11.82(s,1H,OH),11.32(s,1H,NH),7.53(d,J=8.0Hz,2H,ArH),7.34(d,J=8.4Hz,1H,ArH),7.26-7.21(m,4H,ArH),4.86(s,2H,CH2),2.33(s,3H,CH3),1.33(s,9H,(CH3)3C)。
实施例8
按照实施例4的方法,将苯甲酰甲醛换成对溴苯甲酰甲醛,加入(0.2mmol)三氟乙酸,微波反应器于90℃反应40min,用TLC监测反应进程,待反应结束后通过柱层析得到产物,为3-(5,6-亚甲二氧基-2-对溴苯基-1H-吲哚-3-基)-4-羟基呋喃-2(5H)-酮(化合物IVh),收率为73%,熔点为278~279℃。1H NMR(400MHz,DMSO-d6)δ(ppm):12.12(s,1H,OH),11.44(s,1H,NH),7.58(d,J=8.8Hz,2H,ArH),7.53(d,J=8.8Hz,2H,ArH),6.92(s,1H,ArH),6.77(s,1H,ArH),5.96(s,2H,OCH2O),4.84(s,2H,CH2)。
实施例9
按照实施例8的方法,将3,4-亚甲二氧基苯胺(胡椒胺)换成对氯苯胺,加入(0.2mmol)三氟乙酸,微波反应器于90℃反应40min,用TLC监测反应进程,待反应结束后通过柱层析得到产物,为3-(5-氯-2-对溴苯基-1H-吲哚-3-基)-4-羟基呋喃-2(5H)-酮(化合物IVi),收率为61%,熔点为289~290℃。1H NMR(400MHz,DMSO-d6)δ(ppm):12.25(s,1H,OH),11.82(s,1H,NH),7.66-7.59(m,4H,ArH),7.43(d,J=8.4Hz,1H,ArH),7.38(s,1H,ArH),7.16(d,J=8.8Hz,1H,ArH),4.86(s,2H,CH2)。
上述实施例只是为了说明本发明的技术构思及特点,其目的是在于让本领域内的普通技术人员能够了解本发明的内容并据以实施,并不能以此限制本发明的保护范围。凡是根据本发明内容的实质所作出的等效的变化或修饰,都应涵盖在本发明的保护范围内。
Claims (7)
1.一种3-(2-芳基-1H-吲哚-3-基)-4-羟基呋喃-2(5H)-酮,其特征在于,其结构如下所示:
其中,R1为H、4-CH3或4-Br中的任意一种;R2为5-Br、5-CH3、5-(CH3)3C、5,6-OCH2O或4-Cl中的任意一种。
2.一种如权利要求1所述的3-(2-芳基-1H-吲哚-3-基)-4-羟基呋喃-2(5H)-酮的合成方法,其特征在于:该方法是以取代苯甲酰甲醛(式I)、取代苯胺(式II)和季酮酸(式III)为原料,以醇、醚、腈、水、二甲亚砜、N,N-二甲基甲酰胺、醋酸或芳香烃化合物为溶剂,在不使用催化剂,或以无机碱、无机酸、有机酸或有机小分子化合物为催化剂的情况下,在微波辐射下经过三组分反应,一步合成得到目标化合物,一步合成得到目标化合物,即3-(2-芳基-1H-吲哚-3-基)-4-羟基呋喃-2(5H)-酮衍生物(式IV):
3.根据权利要求2所述的3-(2-芳基-1H-吲哚-3-基)-4-羟基呋喃-2(5H)-酮的合成方法,其特征在于:所述溶剂为甲醇、乙醇、1,4-二氧六环、四氢呋喃、乙腈、N,N-二甲基甲酰胺、二甲亚砜、醋酸、甲苯、水或水与乙醇的混合溶剂中的任意一种。
4.根据权利要求2所述的3-(2-芳基-1H-吲哚-3-基)-4-羟基呋喃-2(5H)-酮的合成方法,其特征在于:所述催化剂为碳酸钠、碳酸钾、盐酸、硫酸、醋酸、三氟乙酸、对甲苯磺酸或L-脯氨酸中的任意一种。
5.根据权利要求2所述的3-(2-芳基-1H-吲哚-3-基)-4-羟基呋喃-2(5H)-酮的合成方法,其特征在于:所述取代苯甲酰甲醛、所述取代苯胺、所述季酮酸和所述催化剂的摩尔比为1:1:1:0.1~1:1:1:0.3。
6.根据权利要求2所述的3-(2-芳基-1H-吲哚-3-基)-4-羟基呋喃-2(5H)-酮的合成方法,其特征在于:其反应时间为20~50分钟。
7.根据权利要求2所述的3-(2-芳基-1H-吲哚-3-基)-4-羟基呋喃-2(5H)-酮的合成方法,其特征在于:其反应温度为60~100℃。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610389382.0A CN106008477B (zh) | 2016-06-02 | 2016-06-02 | 3-(2-芳基-1h-吲哚-3-基)-4-羟基呋喃-2(5h)-酮及其合成方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610389382.0A CN106008477B (zh) | 2016-06-02 | 2016-06-02 | 3-(2-芳基-1h-吲哚-3-基)-4-羟基呋喃-2(5h)-酮及其合成方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106008477A true CN106008477A (zh) | 2016-10-12 |
CN106008477B CN106008477B (zh) | 2019-02-26 |
Family
ID=57090487
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610389382.0A Active CN106008477B (zh) | 2016-06-02 | 2016-06-02 | 3-(2-芳基-1h-吲哚-3-基)-4-羟基呋喃-2(5h)-酮及其合成方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106008477B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1660790A (zh) * | 2004-12-21 | 2005-08-31 | 浙江大学 | 2,6-二氰基苯胺衍生物的微波合成方法 |
CN101654425A (zh) * | 2009-09-11 | 2010-02-24 | 浙江工业大学 | L-脯氨酸三氟甲磺酸铵盐及其应用 |
WO2012025155A1 (en) * | 2010-08-26 | 2012-03-01 | Novartis Ag | Hydroxamate-based inhibitors of deacetylases |
-
2016
- 2016-06-02 CN CN201610389382.0A patent/CN106008477B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1660790A (zh) * | 2004-12-21 | 2005-08-31 | 浙江大学 | 2,6-二氰基苯胺衍生物的微波合成方法 |
CN101654425A (zh) * | 2009-09-11 | 2010-02-24 | 浙江工业大学 | L-脯氨酸三氟甲磺酸铵盐及其应用 |
WO2012025155A1 (en) * | 2010-08-26 | 2012-03-01 | Novartis Ag | Hydroxamate-based inhibitors of deacetylases |
Non-Patent Citations (4)
Title |
---|
LI-PING FU,等: ""Three-Component Domino Reactions for Regioselective Formation of Bis-indole Derivatives"", 《ACS COMB. SCI.》 * |
SHAIK KARAMTHULLA,等: ""Microwave-assisted synthesis of novel 2,3-disubstituted imidazo[1,2-a]pyridines via one-pot three component reactions"", 《RSC ADV.》 * |
SHUANG-SHUANG WANG,等: ""Three-component domino [3+2] heterocyclization leading to pyran-3-yl-substituted fused pyrroles"", 《RES CHEM INTERMED》 * |
VSEVOLOD A. PESHKOV,等: ""Three-Component Reaction of a 2-Aminoazine, a 2-Oxoaldehyde, and a Cyclic 1,3-Dicarbonyl Compound for the Synthesis of Imidazo[1,2-a]azine Derivatives"", 《ACS COMB. SCI.》 * |
Also Published As
Publication number | Publication date |
---|---|
CN106008477B (zh) | 2019-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2262766A2 (en) | Amide compounds, compositions and uses thereof | |
Hingane et al. | An efficient new route towards biologically active isocryptolepine and γ-carboline derivatives using an intramolecular thermal electrocyclization strategy | |
Chen et al. | Efficient synthesis of functionalized pyrido [2, 3-c] coumarin derivatives by a one-pot three-component reaction | |
Bharti et al. | Multicomponent synthesis of diverse pyrano-fused benzophenazines using bifunctional thiourea-based organocatalyst in aqueous medium | |
Khoeiniha et al. | Water‐Based Synthesis of Novel 6, 7‐Dihydrobenzofuran‐4 (5H)‐Ones | |
Bhat et al. | An Efficient Three‐component, One‐pot Synthesis of Quinazolines under Solvent‐free and Catalyst‐free Condition | |
Khan et al. | One‐Pot Knoevenagel–Michael–Cyclization Cascade Reaction for the Synthesis of Functionalized Novel 4 H‐pyrans by Using ZnCl2 as a Catalyst | |
Borovlev et al. | SNH Arylamination of 3-Nitropyridine: A Competitive Formation of 2-Arylamino-5-nitropyridines and 2-Arylamino-5-nitrosopyridines | |
Chen et al. | Green Synthesis of 6‐Aryl‐5, 6‐dihydrobenzo [4, 5] imidazo [1, 2‐c] quinazoline Derivatives in Ionic Liquid under Catalyst‐free Conditions | |
Das et al. | A Facile Synthesis of 3-[(N-Alkylanilino)(aryl) methyl] indoles Using TCT | |
CN108947945A (zh) | 一种1,3-二氢异苯并呋喃衍生物及其合成方法和应用 | |
Fodor et al. | A convenient synthesis of 1, 4-benzothiazepines from 1, 3-benzothiazines via the ring transformation of β-lactam-condensed 1, 3-benzothiazine derivatives | |
CN106008477A (zh) | 3-(2-芳基-1h-吲哚-3-基)-4-羟基呋喃-2(5h)-酮及其合成方法 | |
Chen et al. | Solvent-free 1, 3-dipolar cycloaddition of azomethine imines with terminal alkynes promoted by calcium fluoride under the ball milling condition | |
Garud et al. | First regioselective iodocyclization of O-allylselenocarbamates | |
Balalaie et al. | Synthesis of fully functionalized 3-bromoazaspiro [4.5] trienones through Ugi four-component reaction (Ugi-4CR) followed by ipso-bromocyclization | |
Mishina et al. | A new synthesis of 2-aminoindoles and 6-aminopyrrolo [3, 2-d] pyrimidines from π-deficient 1, 2-dihaloarenes and geminal enediamines | |
Myannik et al. | Synthesis of 3-(N-arylcarbamoyl) chromones from 2-hydroxyarylaminoenones and isocyanates | |
CN110272417B (zh) | 2-甲基-1,8-萘啶类化合物及其制备方法与应用 | |
Ibrahimi et al. | Synthesis of 3-benzylphthalide derivatives by using a TDAE strategy | |
Matiychuk et al. | A new method for the synthesis of 1-aryl-1, 2, 4-triazole derivatives | |
Hajishaabanha et al. | Synthesis of furan-fused quinoxaline tetracyclic scaffolds via a three-component isocyanide-based reaction | |
CN102718694B (zh) | 3-氰基取代吲哚化合物及其合成方法 | |
Jourdan et al. | An unusual boron tribromide-mediated, one-pot bromination/cyclization reaction. Application to the synthesis of a highly strained cyclopenta [1, 3] cyclopropa [1, 2-b] pyrrolizin-8-one | |
Voskressensky et al. | Domino reaction of N-(cyanomethyl)-1, 3-azolium quaternary salts with o-hydroxybenzaldehydes: scope and limitations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |